Ranibizumab for the treatment of degenerative ocular conditions

@inproceedings{Triantafylla2014RanibizumabFT,
  title={Ranibizumab for the treatment of degenerative ocular conditions},
  author={Magdalini Triantafylla and Horace F Massa and Doukas Dardabounis and Zisis Gatzioufas and Vassilios P Kozobolis and Konstantinos Ioannakis and Irfan Perente and Georgios D Panos},
  booktitle={Clinical ophthalmology},
  year={2014}
}
Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 142 REFERENCES

Retinitis pigmentosa

C. Hamel
  • Orphanet J Rare Dis
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration

Bert Gold, Joanna E Merriam, +20 authors Heather Stockman
  • Nature Genetics
  • 2006
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL